Discontinued — last reported Q2 '19
Current Assets
Available-for-Sale Debt Securities - Unrealized Loss Position (>=12 Months)
Vertex Pharmaceuticals Available-for-Sale Debt Securities - Unrealized Loss Position (>=12 Months) remained flat by 0.0% to $100.00K in Q3 2025 compared to the prior quarter. Year-over-year, this metric was flat by 0.0%, from $100.00K to $100.00K. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementBalance Sheet Statement
SectionCurrent Assets
CategoryRisk
SignalLower is better
VolatilityStable
First reportedQ3 2017
Last reportedQ2 2019
How to read this metric
Higher values suggest prolonged exposure to unfavorable interest rate environments or potential long-term asset devaluation.
Detailed definition
This metric tracks the unrealized losses on available-for-sale debt securities that have been in a loss position for twe...
Peer comparison
Used by analysts to evaluate the 'stickiness' of unrealized losses in the investment book.
Metric ID:
afs_debt_securities_unrealized_loss_12m_or_longerHistorical Data
9 periods
| Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $53.80M | $3.50M | $100.00K | $100.00K | $100.00K | $100.00K |
| QoQ Change | — | — | — | — | -93.5% | -97.1% | +0.0% | +0.0% | +0.0% |
| YoY Change | — | — | — | — | — | — | -99.8% | -97.1% | +0.0% |
Range$0.00 – $53.80M
Avg YoY Growth-65.7%
Median YoY Growth-97.1%
Current Streak3 quarters growth
Available-for-Sale Debt Securities - Unrealized Loss Position (>=12 Months) at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's available-for-sale debt securities - unrealized loss position (>=12 months)?
- Vertex Pharmaceuticals (VRTX) reported available-for-sale debt securities - unrealized loss position (>=12 months) of $100.00K in Q3 2025.
- How has Vertex Pharmaceuticals's available-for-sale debt securities - unrealized loss position (>=12 months) changed year-over-year?
- Vertex Pharmaceuticals's available-for-sale debt securities - unrealized loss position (>=12 months) decreased by 0.0% year-over-year, from $100.00K to $100.00K.
- What does available-for-sale debt securities - unrealized loss position (>=12 months) mean?
- Unrealized losses on debt investments held for sale that have been losing value for a year or more.